Adjuvant CAPECITABINE in High Risk PSEUDOMYXOMA PERITONEI Patients
Status:
Recruiting
Trial end date:
2023-12-01
Target enrollment:
Participant gender:
Summary
This is a phase II, mono institutional, non comparative study, evaluating adjuvant
capecitabine in patients affected by KRAS mutated Pseudomyxoma peritonei treated with
cytoreductive surgery and HIPEC.
Patient will be treated with 8 cycles of the study regimen that include:
Capecitabine 1250 mg/m2 PO BID day 1-14 q21 days
Phase:
Phase 2
Details
Lead Sponsor:
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano